Skip to content
OpenCapital
Get started

Nuvectis Pharma, Inc. NVCT Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Pfizer logo
PfizerPFE
1.2×0.0×
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
8.8×+7.0×
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
18.3×+13.0×
Nuvation Bio logo
Nuvation BioNUVB
7.2×-1.8×
Immunome logo
ImmunomeIMNM
21.7×+11.2×

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Calculated from Nuvectis Pharma, Inc.’s reported figures.

quick assets/total current liabilities=2.3×

Based on the most recent quarter.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s quick ratio?
Nuvectis Pharma, Inc. (NVCT) reported quick ratio of 2.3× in Q1 2026.
How has Nuvectis Pharma, Inc.'s quick ratio changed year-over-year?
Nuvectis Pharma, Inc.'s quick ratio decreased by 30.7% year-over-year, from 3.3× to 2.3×.
What is the long-term trend for Nuvectis Pharma, Inc.'s quick ratio?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s quick ratio has grown at a -0.3% compound annual growth rate (CAGR), from 2.4× to 2.4×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.